Trametinib dimethyl sulfoxide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Trametinib dimethyl sulfoxide Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
316
Registered trials
369
Result records
3
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Trametinib dimethyl sulfoxide can convert its Small molecule drug profile and MEK1 x MEK2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Trametinib dimethyl sulfoxide (query alias: trametinib) |
|---|---|
| Modality / target | Small molecule drug; MEK1 x MEK2; MEK1 inhibitors, MEK2 inhibitors |
| Highest global status | Approved |
| Originator | GSK Plc |
| Active developers | National Cancer Institute, Novartis Korea Ltd., Novartis Pharmaceuticals Corp. |
The MCP disease footprint includes BRAF V600E Mutation-Positive Differentiated Thyroid Gland Carcinoma, Differentiated Thyroid Gland Carcinoma, BRAF Fusion Glioma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07549646 | Phase 2 | Active, not recruiting | 45 | Percentage of subjects with a Substantial Response or Intermediate Response to Trametinib using an Individualized Response Criteria |
| NCT07477457 | Phase 2 | Recruiting | 45 | 12-month progression free survival (PFS) (cohort 1) |
| NCT07468071 | Phase 1/2 | Recruiting | 40 | Number of participants receiving opnurasib as single agent or in combination with other study treatments |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
The SOS1 Inhibitor BI 1701963 as Monotherapy or in Combination with Trametinib in Patients with <i>KRAS</i> Mutation-Positive Solid Tumors
Phase 1; n=94; evaluation: Negative. Reported fields: AE = All patients experienced adverse events; of note, three monotherapy patients had interstitial lung disease during the first treatment cycle leading to death, considered drug-related by the investigator ; AE = All patients experienced adverse events; of note, three monotherapy patients had interstitial lung disease during the first treatment cycle leading to death, considered drug-related by the investigator
First-line lenvatinib versus dabrafenib plus trametinib (D+T) in BRAF-mutated differentiated thyroid cancer (DTC): Insights from real-world data.
Not Applicable; n=142; evaluation: Positive. Reported fields: Median rwOS = 37.8 Month ( 16.4 - 66.4); Median rwOS = 70.7 Month ( 51.8 - 90.8)
Are all tumor-agnostic biomarkers equally tissue-independent? Comparative cross-histology efficacy analysis of MSI-H/dMMR versus BRAF V600E.
Not Applicable; n=1013; evaluation: Negative. Reported fields: Heterogeneity = 0.149 CV ; Heterogeneity = 0.513 CV
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Trametinib dimethyl sulfoxide addresses BRAF V600E Mutation-Positive Differentiated Thyroid Gland Carcinoma, Differentiated Thyroid Gland Carcinoma, BRAF Fusion Glioma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2025-04-17 | Hikma acquires Novugen’s FDA-approved ANDA for trametinib | Approved | Financial terms not disclosed |
| 2022-12-09 | Erasca partners with Novartis to globally develop and commercialize naporafenib as a treatment for melanoma and other RAS/MAPK pathway-driven tumors. | Approved | US$20.0M upfront; US$280.0M milestones; US$300.0M stated total |
| 2014-04-22 | GSK completes major three-part transaction with Novartis | Phase 2 | US$16,000.0M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Solvates of trametinib”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
